Venlafaxine ER in the treatment of MDD, GAD, SAD and Panic Disorder
Despite multiple adequate trials of antidepressant medications, up to 50% of MDD patients do not see enough improvement in their symptoms. The majority of these patients start treatment with selective serotonin reuptake inhibitors (SSRIs). Residual symptoms are common among patients who remit, and they are linked to worse psychosocial functioning and higher rates of relapse. Up until recently, the main distinctions between antidepressant medications were usually related to tolerability and safety. However in recent years, several studies have been conducted to assess potential variations in antidepressant classes' capacities to alleviate particular depressive symptoms. Due to their diverse ranges of activities, each group of medications in this class has the potential to be used in the treatment of MDD.
Read more
Please login to comment on this Post